Skip to Content


Active Substance: aliskiren / amlodipine
Common Name: aliskiren / amlodipine
ATC Code: C09XA53
Marketing Authorisation Holder: Novartis Europharm Ltd
Active Substance: aliskiren / amlodipine
Status: Withdrawn
Authorisation Date: 2011-04-14
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system

Therapeutic Indication

Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

The marketing authorisation for Rasilamlo has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.